Alnylam Pharmaceuticals, Inc. (ALNY)
| Market Cap | 30.28B -50.3% |
| Revenue (ttm) | 4.80B +95.1% |
| Net Income | 774.71M |
| EPS | 5.62 |
| Shares Out | 133.81M |
| PE Ratio | 40.27 |
| Forward PE | 28.47 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 833,382 |
| Open | 226.24 |
| Previous Close | 224.03 |
| Day's Range | 224.10 - 232.48 |
| 52-Week Range | 197.81 - 485.36 |
| Beta | 0.27 |
| Analysts | Buy |
| Price Target | 367.78 (+62.52%) |
| Earnings Date | Oct 29, 2026 |
About ALNY
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amylo... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 30 analysts, the average rating for ALNY stock is "Buy." The 12-month stock price target is $367.78, which is an increase of 62.52% from the latest price.
News
Alnylam Pharmaceuticals Transcript: Investor update
Initial phase Ib data showed dose-dependent CSF HTT reductions of 60%-64% at month 3, with no reported dose-dependent signals in inflammation, neurofilament or ventricular volume. A pivotal placebo-controlled study is planned for 2027, pending regulatory alignment.
Alnylam Pharmaceuticals Slides: Investor update
Alnylam Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on October 26, 2026.
Alnylam reports ALN-HTT02 clinical trial results
Alnylam (ALNY) reported initial Phase 1b clinical trial results for ALN-HTT02, an investigational RNAi therapeutic in development for the treatment of Huntington’s disease, which will be developed und...
Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's Disease
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported positive initial Phase 1b clinical trial results for ALN-HTT02, a...
Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter endi...
Alnylam assumed with a Buy at UBS
UBS analyst Joon Lee assumed coverage of Alnylam (ALNY) with a Buy rating with a price target of $354, down from $550. The firm states that its bullish conviction is…
Alnylam price target lowered to $253 from $256 at Wells Fargo
Wells Fargo analyst Derek Archila lowered the firm’s price target on Alnylam (ALNY) to $253 from $256 and keeps an Equal Weight rating on the shares ahead of quarterly results.
Alnylam price target lowered to $320 from $340 at Citi
Citi lowered the firm’s price target on Alnylam (ALNY) to $320 from $340 and keeps a Buy rating on the shares ahead of the Q3 report. The firm cites reduced…
Alnylam price target lowered to $336 from $346 at BofA
BofA analyst Tazeen Ahmad lowered the firm’s price target on Alnylam (ALNY) to $336 from $346 and keeps a Buy rating on the shares as the firm has become “more…
Alnylam price target lowered to $345 from $350 at RBC Capital
RBC Capital analyst Luca Issi lowered the firm’s price target on Alnylam (ALNY) to $345 from $350 and keeps an Outperform rating on the shares as part of a broader…
Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Closing Bell Overtime' to talk biotech innovations in China.
Alnylam price target lowered to $369 from $375 at JPMorgan
JPMorgan analyst Jessica Fye lowered the firm’s price target on Alnylam (ALNY) to $369 from $375 and keeps an Overweight rating on the shares. The firm adjusted estimates for Amvuttra…
Alnylam announces launch of AMVUTTRA ‘Play by Play’ initiative
Alnylam (ALNY) Pharmaceuticals announced the launch of AMVUTTRA ‘Play by Play,’ a U.S. educational initiative featuring former professional athletes living with the cardiomyopathy of transthyretin-med...
AMVUTTRA® (vutrisiran) ‘Play by Play' Initiative Highlights Former Athletes' Stories to Shine a Light on the Often-Missed Signs of ATTR-CM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the launch of AMVUTTRA® (vutrisiran) ‘Play by Play,' a U.S. educ...
Alnylam Pharmaceuticals Transcript: Investor update
The update highlighted zilebesiran's potential to transform hypertension care through continuous blood pressure control with twice-yearly dosing, supported by robust phase II data and a large ongoing phase III outcomes trial. Strategic investments and strong stakeholder enthusiasm position the therapy for broad impact if successful.
Alnylam Pharmaceuticals Slides: Investor update
Alnylam Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on September 17, 2026.
Alnylam Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
AMVUTTRA’s rapid growth is supported by strong clinical data, broad access, and a focus on first-line use, with the TTR franchise guidance adjusted to $4.2–$4.5 billion for 2026. The pipeline features promising programs in Huntington’s, bleeding disorders, obesity, and hypertension, while AI partnerships and global expansion are key future drivers.
Alnylam Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference
AMVUTTRA's cardiomyopathy launch has driven strong revenue and first-line market growth, supported by robust access and favorable clinical data. Competitive risks have lessened with tafamidis exclusivity extended and a failed rival trial, while international expansion and pipeline progress in mivelsiran, Huntington's, and bleeding disorders continue to advance.
Alnylam price target raised to $260 from $230 at Jefferies
Jefferies raised the firm’s price target on Alnylam (ALNY) to $260 from $230 and keeps a Hold rating on the shares. After a recent recovery, the firm expects shares to…
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following ...
Alnylam announces new data at ESC Congress on AMVUTTRA
Alnylam (ALNY) Pharmaceuticals announced new data at the European Society of Cardiology, ESC, Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The finding...
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 20...
Alnylam Pharmaceuticals Slides: ESC Congress Presentation
Alnylam Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 30, 2026.
Alnylam to present new clinical data on ATTR, hypertension at ESC Congress
Alnylam (ALNY) Pharmaceuticals announced that it will present new clinical and real-world data across its transthyretin-mediated amyloidosis, ATTR, and hypertension programs at the European Society of...
Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it will present new clinical and real-world data across its...